MULTIPLE
THERAPIES,
ONE VIRUS.
KALIVIR is developing cutting-edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer. PRESENTATIONS READ MORE Nov 10, 2022 – KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting READ MORE NEWS AND EVENTS Novel Vaccinia Enhanced Template (VET) Oncolytic Platform
LEARN MORE